Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Easywell Biomedicals's FCF Margin % or its related term are showing as below:
ROCO:1799'
s FCF Margin % Range Over the Past 10 Years
Min: -85.7 Med: -63.99 Max: 18.31
Current: 18.31
During the past 13 years, the highest FCF Margin % of Easywell Biomedicals was 18.31%. The lowest was -85.70%. And the median was -63.99%.
ROCO:1799's FCF Margin % is ranked better than 86.71% of 963
companies
in the Drug Manufacturers industry
Industry Median: 2.55
vs ROCO:1799: 18.31
Easywell Biomedicals FCF Margin % Related Terms
Easywell Biomedicals FCF Margin % Historical Data
* Premium members only.
The historical data trend for Easywell Biomedicals's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Easywell Biomedicals's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Easywell Biomedicals FCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Easywell Biomedicals's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Easywell Biomedicals's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Easywell Biomedicals (ROCO:1799) has a FCF Margin % of 15.89% as of Dec. 2025. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Easywell Biomedicals and its competitors. According to the industry distribution chart, Easywell Biomedicals ranks #128 out of 963 companies in the Drug Manufacturers industry, placing it in the top 13.3%.
Is Easywell Biomedicals' FCF Margin % too high?
Easywell Biomedicals' current FCF Margin % is 15.89%. The Drug Manufacturers industry median FCF Margin % is 2.55. Easywell Biomedicals' value of 15.89% is 523.1% above this industry median. Based on the distribution chart, Easywell Biomedicals ranks #128 out of 963 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Easywell Biomedicals has a GF Score™ of 55/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Easywell Biomedicals' FCF Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Easywell Biomedicals ranks #128 out of 963 companies for FCF Margin %. This places Easywell Biomedicals in the top 13% of its industry — outperforming the majority of peers. The industry median FCF Margin % is 2.55. Easywell Biomedicals' value of 15.89% is 523.1% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Drug Manufacturers company?
The median FCF Margin % among Drug Manufacturers companies is 2.55, based on 963 companies in the industry. Companies in the top quartile (top 25%) have a FCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Easywell Biomedicals's current FCF Margin % of 15.89% is 523.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Easywell Biomedicals and its competitors. For the Drug Manufacturers industry, the median FCF Margin % is 2.55 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Easywell Biomedicals's current FCF Margin % is 15.89%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Easywell Biomedicals stock overvalued right now?
Based on GuruFocus' analysis, Easywell Biomedicals (ROCO:1799) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$75.37, compared to a current price of NT$32.25 — trading 57.2% below its estimated fair value. The current FCF Margin % is 15.89% and 523.1% above the Drug Manufacturers industry median of 2.55. Easywell Biomedicals' overall GF Score™ is 55/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Easywell Biomedicals (ROCO:1799), the current FCF Margin % is 15.89% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Easywell Biomedicals (ROCO:1799) Overvalued in 2026?
Based on GuruFocus' analysis, Easywell Biomedicals stock appears to be undervalued.
The current stock price of NT$32.25 is trading 57.2% below its estimated GF Value™ of NT$75.37.
GuruFocus considers Easywell Biomedicals to be Significantly Undervalued.
Key valuation signals for ROCO:1799:
FCF Margin %: 15.89%
GF Value™: NT$75.37 vs. price of NT$32.25 (57.2% below fair value)
Industry Position: 523.1% above the Drug Manufacturers median (#128 of 963)
No single metric tells the full story. See the ROCO:1799 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Easywell Biomedicals Inc is engaged in drug development, manufacturing, and sales of active pharmaceutical ingredients, generic drugs, and new drugs. It focuses on complex generics, new drug delivery platforms, and regenerative medicines, with cGMP. The company's segments include the Drug Development segment and the Other segment. Geographically, the company operates in America, China, and Taiwan regions.
55GF Score
Get the complete analysis for ROCO:1799
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:1799 has been successfully added to your 
